David Altshuler - Feb 17, 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Global Research and CSO
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
Feb 17, 2023
Transactions value $
-$2,273,864
Form type
4
Date filed
2/22/2023, 03:25 PM
Previous filing
Feb 16, 2023
Next filing
Feb 28, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Tax liability -$1.1M -3.75K -7.81% $292.85 44.2K Feb 17, 2023 Direct
transaction VRTX Common Stock Sale -$10.5K -36 -0.08% $291.01 44.2K Feb 21, 2023 Direct F1
transaction VRTX Common Stock Sale -$358K -1.22K -2.77% $292.76 43K Feb 21, 2023 Direct F1, F2, F3
transaction VRTX Common Stock Sale -$542K -1.84K -4.29% $294.03 41.1K Feb 21, 2023 Direct F1, F2, F4
transaction VRTX Common Stock Sale -$265K -900 -2.19% $294.73 40.2K Feb 21, 2023 Direct F1, F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1.
F2 Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $292.76 (range $292.25 to $293.12).
F4 Open market sales reported on this line occurred at a weighted average price of $294.03 (range $293.45 to $294.42).
F5 Open market sales reported on this line occurred at a weighted average price of $294.73 (range $294.47 to $295.37).